Robin Kramer Biogen Inc. (BIIB) insider trading activity

Robin Kramer is Chief Accounting Officer of BIOGEN INC.. Currently has a direct ownership of 6,226 shares of BIIB, which is worth approximately $1.08 Million. The most recent transaction as insider was on Feb 16, 2024, when has been sold 396 shares (Common Stock) at a price of $219.08 per share, resulting in proceeds of $86,755. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 6.23K

0% 3M change

56.71% 12M change

Total Value Held $1.08 Million

Robin Kramer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 16 2024	SELL Payment of exercise price or tax liability	$86,755 $219.08 p/Share	396 Reduced 5.98%	6,226 Common Stock
Feb 16 2024	BUY Exercise of conversion of derivative security	-	1,345 Added 17.47%	6,353 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$59,040 $240.98 p/Share	245 Reduced 4.44%	5,277 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	833 Added 13.11%	5,522 Common Stock
Feb 08 2024	SELL Payment of exercise price or tax liability	$60,795 $240.3 p/Share	253 Reduced 5.12%	4,689 Common Stock
Feb 08 2024	BUY Exercise of conversion of derivative security	-	788 Added 13.75%	4,942 Common Stock
Dec 08 2023	SELL Payment of exercise price or tax liability	$40,679 $239.29 p/Share	170 Reduced 3.93%	4,154 Common Stock
Dec 08 2023	BUY Exercise of conversion of derivative security	-	351 Added 7.51%	4,324 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$34,751 $284.85 p/Share	122 Reduced 2.98%	3,973 Common Stock
Jun 30 2023	BUY Exercise of conversion of derivative security	-	252 Added 5.8%	4,095 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$66,254 $278.38 p/Share	238 Reduced 6.67%	3,331 Common Stock
Feb 17 2023	BUY Exercise of conversion of derivative security	-	512 Added 11.76%	3,843 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$168,917 $286.3 p/Share	590 Reduced 14.19%	3,569 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	-	1,061 Added 21.4%	3,897 Common Stock
Jan 25 2023	BUY Grant, award, or other acquisition	-	887 Added 22.26%	3,098 Common Stock
Dec 08 2022	SELL Payment of exercise price or tax liability	$45,099 $289.1 p/Share	156 Reduced 6.59%	2,211 Common Stock
Dec 08 2022	BUY Exercise of conversion of derivative security	-	350 Added 12.88%	2,367 Common Stock
Jul 01 2022	SELL Payment of exercise price or tax liability	$15,587 $210.63 p/Share	74 Reduced 3.54%	2,017 Common Stock
Jul 01 2022	BUY Exercise of conversion of derivative security	-	252 Added 10.76%	2,091 Common Stock
Feb 18 2022	SELL Payment of exercise price or tax liability	$24,545 $209.79 p/Share	117 Reduced 6.31%	1,737 Common Stock
Feb 18 2022	BUY Exercise of conversion of derivative security	-	396 Added 17.6%	1,854 Common Stock
Feb 12 2022	SELL Payment of exercise price or tax liability	$36,695 $214.59 p/Share	171 Reduced 10.5%	1,458 Common Stock
Feb 12 2022	BUY Exercise of conversion of derivative security	-	275 Added 14.71%	1,594 Common Stock
Jan 19 2022	BUY Grant, award, or other acquisition	-	244 Added 15.27%	1,354 Common Stock
Dec 03 2021	SELL Payment of exercise price or tax liability	$22,392 $223.92 p/Share	100 Reduced 8.26%	1,110 Common Stock

Also insider at

ARMP

Armata Pharmaceuticals, Inc. Healthcare

Director

Robin Kramer

Chief Accounting Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BIIB shares.

Notify only if

Value

Insider Trading

Get notified when an Biogen Inc. insider buys or sells BIIB shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOGEN INC.

Track Activities on BIIB

Account